6/26/2013

The FDA has granted orphan drug exclusivity to Raptor Pharmaceutical's nephropathic cystinosis drug Procysbi, a delayed-release capsule formulation of cysteamine bitartrate. The designation gives the drug, which was approved on April 30, seven years of exclusivity.

Related Summaries